CHMP backs GSK's albiglutide, Bayer's riociguat

EMA's CHMP backed approval of Eperzan albiglutide from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) as monotherapy or as add-on therapy for Type II diabetes. A BLA for albiglutide -- a glucagon-like peptide-1 (GLP-1) receptor agonist comprised of two copies of modified human GLP-1 fused in series to human albumin -- is also under FDA review, with an April 15 PDUFA date. ...